Rock Springs Capital Management LP Has $8.38 Million Stock Position in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Rock Springs Capital Management LP boosted its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 2.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,779,575 shares of the company's stock after acquiring an additional 150,336 shares during the period. Rock Springs Capital Management LP owned approximately 4.20% of Compass Therapeutics worth $8,380,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its position in Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after purchasing an additional 12,917 shares during the period. Independent Advisor Alliance bought a new stake in Compass Therapeutics in the fourth quarter valued at about $26,000. Mariner LLC bought a new position in Compass Therapeutics during the fourth quarter worth about $30,000. XTX Topco Ltd bought a new position in Compass Therapeutics during the third quarter worth about $37,000. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Compass Therapeutics in the 4th quarter valued at approximately $45,000. Institutional investors and hedge funds own 68.43% of the company's stock.

Insiders Place Their Bets

In related news, insider Jonathan Anderman acquired 20,000 shares of the company's stock in a transaction that occurred on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the acquisition, the insider now owns 21,000 shares of the company's stock, valued at $32,340. This trade represents a 2,000.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The disclosure for this sale can be found here. Company insiders own 28.50% of the company's stock.

Compass Therapeutics Trading Down 8.5 %

Shares of CMPX traded down $0.18 during trading hours on Friday, hitting $1.94. 877,992 shares of the stock traded hands, compared to its average volume of 874,372. The business has a fifty day moving average of $2.23 and a 200-day moving average of $2.10. The firm has a market capitalization of $268.27 million, a PE ratio of -5.24 and a beta of 1.40. Compass Therapeutics, Inc. has a 1-year low of $0.77 and a 1-year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities research analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on CMPX. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Piper Sandler assumed coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 target price on the stock. Jefferies Financial Group boosted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. D. Boral Capital reiterated a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Monday, April 21st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 21st. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Compass Therapeutics currently has a consensus rating of "Buy" and an average price target of $13.38.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.